Targeting Uremic Toxins to Prevent Peripheral Vascular Complications in Chronic Kidney Disease.
Chia-Lin WuDer-Cherng TarngPublished in: Toxins (2020)
Chronic kidney disease (CKD) exhibits progressive kidney dysfunction and leads to disturbed homeostasis, including accumulation of uremic toxins, activated renin-angiotensin system, and increased oxidative stress and proinflammatory cytokines. Patients with CKD are prone to developing the peripheral vascular disease (PVD), leading to poorer outcomes than those without CKD. Cumulative evidence has showed that the synergy of uremic milieu and PVD could exaggerate vascular complications such as limb ischemia, amputation, stenosis, or thrombosis of a dialysis vascular access, and increase mortality risk. The role of uremic toxins in the pathogenesis of vascular dysfunction in CKD has been investigated. Moreover, growing evidence has shown the promising role of uremic toxins as a therapeutic target for PVD in CKD. This review focused on uremic toxins in the pathophysiology, in vitro and animal models, and current novel clinical approaches in reducing the uremic toxin to prevent peripheral vascular complications in CKD patients.
Keyphrases
- chronic kidney disease
- end stage renal disease
- oxidative stress
- escherichia coli
- risk factors
- peritoneal dialysis
- adipose tissue
- newly diagnosed
- ischemia reperfusion injury
- dna damage
- mass spectrometry
- chemotherapy induced
- cancer therapy
- high resolution
- metabolic syndrome
- prognostic factors
- lower limb
- skeletal muscle
- endoplasmic reticulum stress
- induced apoptosis
- patient reported outcomes
- glycemic control
- single molecule
- insulin resistance